ABLYNX (ABLYF) Downgraded by Zacks Investment Research to “Hold”

Zacks Investment Research downgraded shares of ABLYNX (OTCMKTS:ABLYF) from a buy rating to a hold rating in a research note issued to investors on Friday morning.

According to Zacks, “Ablynx NV is a biopharmaceutical company which engaged in the development of Nanobodies (R) proprietary therapeutic proteins based on single-domain antibody fragments. The company also discovers and develops therapeutic for inflammation, haematology, immuno-oncology, oncology and respiratory disease. Ablynx NV is headquartered in Ghent, Belgium. “

Separately, Bank of America started coverage on shares of ABLYNX in a report on Friday, November 10th. They issued a buy rating and a $26.00 target price for the company.

ABLYNX (OTCMKTS ABLYF) remained flat at $$38.48 during trading on Friday. ABLYNX has a 12-month low of $11.10 and a 12-month high of $50.00.

COPYRIGHT VIOLATION WARNING: “ABLYNX (ABLYF) Downgraded by Zacks Investment Research to “Hold”” was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.thelincolnianonline.com/2018/01/13/ablynx-ablyf-downgraded-by-zacks-investment-research-to-hold.html.

ABLYNX Company Profile

Ablynx NV, a biopharmaceutical company, develops Nanobodies that is a proprietary therapeutic protein based on single-domain antibody fragments for the treatment of various diseases. The company develops products in various therapeutic areas, such as inflammation, hematology, immuno-oncology, oncology, and respiratory diseases.

Receive News & Ratings for ABLYNX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABLYNX and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply